Weiss K B, Sullivan S D
CMAJ. 1996 Mar 15;154(6):841-3.
The authors comment on Dr. Murray Krahn and associates' findings on the direct and indirect costs of asthma in Canada in 1990 (see pages 821 to 831 of this issue). They believe this study is the most meticulous of recent cost-of-illness analyses of the economic burden of asthma. They argue that although Krahn and associates' study is a useful addition to the economic literature on this common disorder, the cost-of-illness method of analysis cannot address the question of the relative costs and benefits of specific interventions. The next task in improving the management of asthma is therefore to undertake studies that will allow clinical and administrative decision-makers to assess the relative cost-effectiveness of a range of available treatments.
作者对默里·克兰博士及其同事关于1990年加拿大哮喘直接和间接成本的研究结果发表评论（见本期第821至831页）。他们认为这项研究是近期关于哮喘经济负担的疾病成本分析中最为细致的。他们指出，尽管克兰及其同事的研究对关于这种常见疾病的经济文献是一项有益补充，但疾病成本分析方法无法解决特定干预措施的相对成本和效益问题。因此，改善哮喘管理的下一项任务是开展研究，使临床和行政决策者能够评估一系列现有治疗方法的相对成本效益。
